Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Infasurf

Executive Summary

Marketing of the lung surfactant calfactant will begin in October, following Buffalo federal court ruling that Infasurf does not infringe Abbott's Survanta (beractant) patent. The ruling overturns a lower court decision against Forest in September. Infasurf was approved in July 1998 for respiratory distress syndrome (1"The Pink Sheet" July 13, p. 4)

You may also be interested in...



Dey Curosurf Low Volume Dosing May Be Differentiating Point For Surfactant

Dey may highlight low volume dosing as a way to differentiate its newly approved surfactant product Curosurf from other surfactants.

Dey Curosurf Low Volume Dosing May Be Differentiating Point For Surfactant

Dey may highlight low volume dosing as a way to differentiate its newly approved surfactant product Curosurf from other surfactants.

Forest Celexa On Pace To Exceed $300 Mil.; W-L Nearing Payments

Warner-Lambert expects to begin earning co-promotion income from its marketing efforts for Forest's Celexa (citalopram) in the next quarter.

Related Content

UsernamePublicRestriction

Register

PS034437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel